Abeona Therapeutics Inc (ABEO) Stock Price, Chart & News

Earn 10$ Cash for every Pro+ Friend you Refer!

ABEO

5.15

USD0.061.18%

Overview

Profile

Statistics

Earnings

Financials

Holders

Trends

Insider Trades

Filings

News

Chart

Analysts Recommendations

Bullish

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Day Range

5.12USD

5.18USD

52 Week Range

3.05USD

9.01USD

Market Cap

244.56MUSD

About

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases. Its lead clinical program is EB-101, an autologous, engineered cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company develops ABO-503 for the treatment of X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 for the treatment of autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. is headquartered in Cleveland, Ohio.

General Information

Type

Common Stock

Exchange

NASDAQ

Currency Code

USD

Currency Name

US Dollar

Country Name

USA

Country ISO

ISIN

US00289Y1073

CUSIP

00431M308

Sector

Healthcare

Industry

Biotechnology

Fiscal Year End

December

IPO date

Updated At

Highlights

PE Ratio

PEG Ratio

Book Value

0.56

Dividend Share

Dividend Yield

Earnings Share

-2.05

Wall Street Target Price

15.9

EPS Estimate Current Year

-1.56

EPS Estimate Next Year

-1.125

EPS Estimate Current Quarter

-0.415

EPS Estimate Next Quarter

-0.415

Most Recent Quarter

Profitability

Revenue TTM

Gross Profit TTM

-31,287,000

EBITDA

-54,747,000

Profit Margin

0.00%

Return On Assets TTM

-37.81%

Return On Equity TTM

-127.38%

Revenue Per Share TTM

Qtly Revenue Growth YOY

-100.00%

Diluted Eps TTM

-2.05

Qtly Earnings Growth YOY

0.00%

Valuation

Trailing PE

0.00

Forward PE

Price Sales TTM

61.6302

Price Book MRQ

4.834

Enterprise Value Revenue

Enterprise Value EBITDA

Peers analysis

ALNYAlnylam Pharmaceuticals Inc
248.87
3.50%
CMXHFCSL Limited
169.54
3.19%
BNTXBioNTech SE
115.69
3.05%
VRTXVertex Pharmaceuticals Inc
419.47
1.89%
REGNRegeneron Pharmaceuticals Inc
700.98
1.49%

CSLLYCSL Ltd
86.83
0.51%
ARGNFargenx SE
655.00
0.00%
UCBJFUCB SA
194.85
0.00%
ARGXargenx NV ADR
660.20
-0.82%
UCBJYUCB SA ADR
97.63
-0.27%

What are you waiting for?Start making profit today

Tools

Plans

Markets

Resources

Compare

Profit mobile app

Discover the world of finance in your pocket

2025